The evaluation of the cardiovascular events in patients with atrial fibrillation in the long-term after "maze" radiofrequency endocardial catheter ablation procedure
https://doi.org/10.29001/2073-8552-2015-30-1-60-66
Abstract
The aim of this study was to evaluate the occurrence of cardiovascular events in the long-term period after “MAZE” radiofrequency endocardial catheter ablation procedure, according to the efficacy of the interventional treatment. A total of 391 patients (247 male) aged 18 to 77 years (mean age 54.9±10.1 years) with atrial fibrillation (AF) were examined. All patients underwent catheter ablation, including pulmonary veins isolation and ablation of the lines in the back wall, roof of the left atrium, and the mitral isthmus. According to the results of our study, the long-term efficacy was 83.3% in patients with paroxysmal AF and about 72.4% in patients with persistent AF. Maintaining the sinus rhythm significantly reduced the risk of stroke (including fatal stroke) as compared with single anticoagulation therapy during the heart rate control strategy.
About the Authors
M. E. Protasov
Republican Cardiology Dispensary
Russian Federation
Russian Federation
R. E. Batalov
Federal State Budgetary Scientific Institution "Research Institute for Cardiology"
Russian Federation
Russian Federation
M. S. Khlynin
Federal State Budgetary Scientific Institution "Research Institute for Cardiology"
Russian Federation
Russian Federation
E. A. Protasova
Saratov State Medical University n.a. V.I. Razumovsky, Research Institute for Cardiology
Russian Federation
Russian Federation
I. V. Kisteneva
Federal State Budgetary Scientific Institution "Research Institute for Cardiology"
Russian Federation
Russian Federation
S. V. Popov
Federal State Budgetary Scientific Institution "Research Institute for Cardiology"
Russian Federation
Russian Federation
References
1. Connoly S.J., Ezenkowitz M.D., Yusuf S. For the Dabigatran versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. -2009. - Vol. 361. - P. 1139-1151.
2. Go A., Hylek E., Phillips K. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study // Jama. - 2001. - Vol. 285. - P. 2370-2375.
3. Granger C.B., Alexander J.H., McMurray J.J. For the ARISTOTLE Commitees and Investigators. Apixaban and Warfarin in patients with atrial fibrillation // N. Engl. J. Med. - 2011. - Vol. 365. -P. 981-992.
4. Heart R., Pearce L., Aguilar M. Meta-analysis: antithrombotic therapy to prevent stoke in patients who have nonvalvular atrial fibrillation // Ann. Instern. Med. - 2007. - No. 146. - P. 857867.
5. Heeringa J., van der Kuip D., Hofman А. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study // Eur. Heart J. - 2006. - No. 27. - Р 949-953.
6. Miyasaka Y., Barnes M., Gersh B. Secular trends in incidence of atrial fibrillation in Olmsted Country, Minnesota, 1980 to 2000, and implications on the projections for future prevalence // Circulation. - 2006. - Vol. 114. - P. 119-125.
7. Naccarelli G., Varker H., Lin J., Schulman K. Increasing prevalence of atrial fibrillation and flutter in the United States // Am. J. Cardiology. - 2009. - Vol. 104. - P. 1534-1939.
8. Stewart S., Hart C., Hole D. et al. Population prevalence, incidence and predictors of atrial fibrillation in the Renfrew/Paisley study // Heart. - 2001. - No. 86. - P. 516-521.
9. Prystowsky E., Katz A. Atrial fibrillation in textbook of cardiovascular medicine. - Philadelphia: Lippincott-Raven, 1998. - P. 1661.
10. Patel M.R., Mahaffey K.W., Garg J. For the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. - 2011. - Vol. 365. - P. 883-891.
11. Wann S., Curtis B., Januaru T 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 Guideline) // Heart Rhythm. - 2011. -Vol. 8. - Р 158-176.
12. Wyse D. The Euro Heart Survey on atrial fibrillation // Eur. Heart J. - 2005. - Vol. 26(22). - Р. 2356-2357.
13. Баталов РЕ., Попов С.В., Егай Ю.В. Лечение фибрилляции предсердий (обзор литературы) // Сибирский медицинский журнал (Томск). - 2011. - Т. 26, № 4. - С. 8-14.
14. Гуляров М.Ю., Магомадова М.У., Сулимов В.А. Алгоритм подборы дозы варфарина с учетом носительства полиморфизмов генов цитохрома CYP2C9 и субъединицы 1 витамин К эпоксиредуктазы // Вестник аритмологии. - 2011. - № 63. - С. 28-30.
15. Татарский Б.А., Баталов Р.Е., Попов С.В. Фибрилляция предсердий: патофизиологические подходы к выбору антиаритмической терапии. - Томск: STT, 2013. - 484 с.
16. Шубик Ю.В. Антитромботическая терапия при фибрилляции предсердий // Вестник аритмологии. - 2014. - № 75. -С. 50-75.
Review
For citations:
Protasov M.E., Batalov R.E., Khlynin M.S., Protasova E.A., Kisteneva I.V., Popov S.V. The evaluation of the cardiovascular events in patients with atrial fibrillation in the long-term after "maze" radiofrequency endocardial catheter ablation procedure. Siberian Journal of Clinical and Experimental Medicine. 2015;30(1):60-66. (In Russ.) https://doi.org/10.29001/2073-8552-2015-30-1-60-66
Views:
226
.png)
Email this article 